Fertility Issues in the Patient with Testis Cancer

  • Dana A. Ohl
  • Jens Sonksen


In the past 20 years a marked improvement in the outlook for men with testis cancer has been achieved, aided by advances in imaging technologies, which now can better diagnose the presence or absence of metastatic disease, and refinements in surgical and anesthetic techniques for excision of difficult, persistent metastatic lesions. The most marked change, however, has come from the development of effective chemotherapy for the treatment of metastatic lesions. In the 1990s, it is expected that >95% of men with low-volume metastatic testicular cancer will survive their neoplasm.1


Assisted Reproductive Technology Testicular Cancer Sperm Count Undescended Testis Testis Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Horwich A, Norman A, Fisher C, et al. Primary chemotherapy for stage 11 nonseminomatous germ cell tumors of the testis. J Urol 1994; 151: 72–77.PubMedGoogle Scholar
  2. 2.
    Nijman JM, Schraffordt-Koops H, Kremer J, et al. Fertility and hormonal function in patients with a nonseminomatous tumor of the testis. Arch Androl 1985; 14: 239–246.PubMedCrossRefGoogle Scholar
  3. 3.
    Drasga RE, Einhorn LH, Williams SD, et al. Fertility after chemotherapy for testicular cancer. J Clin Oncol 1983; 1: 179–183.PubMedGoogle Scholar
  4. 4.
    Hendry WF, Stedronska J, Jones CR, et al. Semen analysis in testicular cancer and Hodgkin’s disease: pre-and post-treatment findings and implications for cryopreservation. Br J Urol 1983; 55: 769–773.PubMedCrossRefGoogle Scholar
  5. 5.
    Berthelsen JG. Sperm counts and serum follicle-stimulating hormone levels before and after radiotherapy and chemotherapy in men with testicular germ cell cancer. Fertil Steril 1984; 41: 281–286.PubMedGoogle Scholar
  6. 6.
    Fossa SD, Abyholm T, Aakvaag A. Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment. Eur Urol 1984; 10: 173–177.PubMedGoogle Scholar
  7. 7.
    Bouchot O, Plougastel ML, Karam G, et al. [Sterility and tumors of the testis. Study of late exocrine and endocrine functions in stage I or IIA tumors]. J Urol (Paris) 1989; 95: 367371.Google Scholar
  8. 8.
    Fossa SD, Aabyholm T, Vespestad S, et al. Semen quality after treatment for testicular cancer. Eur Urol 1993; 23: 172–176.PubMedGoogle Scholar
  9. 9.
    Ferreira U, Netto NRJ, Esteves SC, et al. Comparative study of the fertility potential of men with only one testis. Scand J Urol Nephrol 1991; 25: 255–259.PubMedCrossRefGoogle Scholar
  10. 10.
    Fossa SD, Theodorsen L, Norman N, et al. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril 1990; 54: 493–496.PubMedGoogle Scholar
  11. 11.
    Foster RS, Rubin LR, McNulty A, et al. Detection of antisperm-antibodies in patients with primary testicular cancer. Int J Androl 1991; 14: 179–185.PubMedCrossRefGoogle Scholar
  12. 12.
    Guazzieri S, Lembo A, Ferro G, et al. Sperm antibodies and infertility in patients with testicular cancer. Urology 1985; 26: 139–142.PubMedCrossRefGoogle Scholar
  13. 13.
    Hobarth K, Klingler HC, Maier U, et al. Incidence of antisperm antibodies in patients with carcinoma of the testis and in subfertile men with normogonadotropic oligoasthenoteratozoospermia. Urol Int 1994; 52: 162–165.PubMedCrossRefGoogle Scholar
  14. 14.
    Lefebvre H, Laquerriere A, Cleret JM, et al. A hCG-secreting testicular seminoma revealed by male infertility: mechanism of hCG-evoked en-docrine disturbances. Andrologia 1993; 25: 283–287.PubMedCrossRefGoogle Scholar
  15. 15.
    Carroll PR, Whitmore WFJ, Herr HW, et al. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J Urol 1987; 137: 420–423.PubMedGoogle Scholar
  16. 16.
    Sharma RK, Tolentino MV, Thomas AJ, et al. Optimal dose and duration of exposure to artificial stimulants in cryopreserved human spermatozoa. J Urol 1996; 155: 568–573.PubMedCrossRefGoogle Scholar
  17. 17.
    Chilvers C, Dudley NE, Gough MH, et al. Undescended testis: the effect of treatment on subsequent risk of subfertility and malignancy. J Pediatr Surg 1986; 21: 691–696.PubMedCrossRefGoogle Scholar
  18. 18.
    Muller J, Skakkebaek NE, Nielsen OH, et al. Cryptorchidism and testis cancer. Atypical infantile germ cells followed by carcinoma in situ and invasive carcinoma in adulthood. Cancer 1984; 54: 629–634.PubMedCrossRefGoogle Scholar
  19. 19.
    Muller J, Skakkebaek NE, Ritzen M, et al. Carcinoma in situ of the testis in children with 45,X/ 46,XY gonadal dysgenesis. J Pediatr 1985; 106: 431–446.PubMedCrossRefGoogle Scholar
  20. 20.
    Andres TL, Trainer TD, Leadbetter GW. Atypical germ cells preceding metachronous bilateral testicular tumors. Urology 1980; 15: 307–309.PubMedCrossRefGoogle Scholar
  21. 21.
    Daugaard G, Giwercman A, Skakkebaek NE. Should the other testis be biopsied? Semin Urol 1996; 14: 8–12.Google Scholar
  22. 22.
    Berthelsen JG, Skakkebaek NE. Gonadal function in men with testis cancer. Fertil Steril 1983; 39: 68–75.PubMedGoogle Scholar
  23. 23.
    Pryor JP, Cameron KM, Chilton CP, et al. Carcinoma in situ in testicular biopsies from men presenting with infertility. Br J Urol 1983; 55: 780–784.PubMedCrossRefGoogle Scholar
  24. 24.
    Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 1978; 2: 157–170.PubMedCrossRefGoogle Scholar
  25. 25.
    Bettocchi C, Coker CB, Deacon J, et al. A review of testicular intratubular germ cell neoplasia in infertile men. J Androl 1994; 15: 14S - 16S.PubMedGoogle Scholar
  26. 26.
    Nistal M, Codesal J, Paniagua R. Carcinoma in situ of the testis in infertile men. A histological, immunocytochemical, and cytophotometric study of DNA content. J Pathol 1989; 159: 205–210.PubMedCrossRefGoogle Scholar
  27. 27.
    Giwercman A, Muller J, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes from 399 men who died suddenly and unexpectedly. J Urol 1991; 145: 77–80.PubMedGoogle Scholar
  28. 28.
    Centola GM, Keller JW, Henzler M, et al. Effect of low-dose testicular irradiation on sperm count and fertility in patients with testicular seminoma. J Androl 1994; 15: 608–613.PubMedGoogle Scholar
  29. 29.
    Littley MD, Shalet SM, Morgenstern GR, et al. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med 1991; 78: 265–274.PubMedGoogle Scholar
  30. 30.
    Giwercman A, von der Maase H, Berthelsen JG, et al. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991; 73: 596–603.PubMedCrossRefGoogle Scholar
  31. 31.
    Brennemann W, Brensing KA, Leipner N, et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D- tryptophan-6 luteinizing hormone releasing hormone. Clin Invest 1994; 72: 838–842.CrossRefGoogle Scholar
  32. 32.
    Fossa SD, Abyholm T, Normann N, et al. Post-treatment fertility in patients with testicular cancer. III. Influence of radiotherapy in seminoma patients. Br J Urol 1986; 58: 315–319.PubMedCrossRefGoogle Scholar
  33. 33.
    Bracken RB, Johnson DE. Sexual function and fecundity after treatment for testicular tumors. Urology 1976; 7: 35–38.PubMedCrossRefGoogle Scholar
  34. 34.
    Malas S, Levin V, Sur RK, et al. Fertility in patients treated with radiotherapy following orchidectomy for testicular seminoma. Clin Oncol (R Coll Radiol) 1994; 6: 377–380.CrossRefGoogle Scholar
  35. 35.
    Fossa SD, Almaas B, Jetne V, et al. Paternity after irradiation for testicular cancer. Acta Radiol Oncol 1986; 25: 33–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Fossa SD, Ous S, Abyholm T, et al. Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 1985; 57: 210–214.PubMedCrossRefGoogle Scholar
  37. 37.
    Johnson DH, Hainsworth JD, Linde RB, et al. Testicular function following combination chemotherapy with cisplatin, vinblastine, and bleomycin. Med Pediatr Oncol 1984; 12: 233–238.PubMedCrossRefGoogle Scholar
  38. 38.
    Kreuser ED, Harsch U, Hetzel WD, et al. Chronic gonadal toxicity in patients with testicular cancer after chemotherapy. Eur J Cancer Clin Oncol 1986; 22: 289–294.PubMedCrossRefGoogle Scholar
  39. 39.
    Poirier S, Einhorn LH, Rubin L. Evaluation of reproductive capacity in germ cell tumor patients following chemotherapy with cisplatin, VP-16 and bleomycin (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1992; A1313.Google Scholar
  40. 40.
    Fossa SD, Klepp O, Norman N. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer. Br J Urol 1988; 62: 449–453.PubMedCrossRefGoogle Scholar
  41. 41.
    Kreuser ED, Klingmuller D, Thiel E. The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol 1993; 23: 157–164.PubMedGoogle Scholar
  42. 42.
    Krause W, Pfluger KH. Treatment with the gonadotropin-releasing hormone agonist buse-relin to protect spermatogenesis against cytotoxic treatment in young men. Andrologia 1989; 21: 265–270.PubMedCrossRefGoogle Scholar
  43. 43.
    Kedia KR, Markland C, Fraley EE. Sexual function following high retroperitoneal lymphade-nectomy. J Urol 1975; 114: 237–239.PubMedGoogle Scholar
  44. 44.
    Nijman JM, Schraffordt KH, Oldhoff J, et al. Sexual function after bilateral retroperitoneal lymph node dissection for nonseminomatous testicular cancer. Arch Androl 1987; 18: 255–267.PubMedCrossRefGoogle Scholar
  45. 45.
    Lange PH, Narayan P, Fraley EE. Fertility issues following therapy for testicular cancer. Semin Urol 1984; 2: 264–274.PubMedGoogle Scholar
  46. 46.
    Jewett MAS, Kong YS, Goldberg SD, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation./Urol 1988; 139: 1220–1224.Google Scholar
  47. 47.
    Donohue JP, Foster RS, Rowland RG, et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 1990; 144: 287–291.PubMedGoogle Scholar
  48. 48.
    Weidner W, Zoller G, Sauerwein D, et al. A modified technique for nerve-sparing retroperitoneal lymph node dissection in stage II nonseminomatous germ cell tumors using intraoperative measurement of bladder neck pressure alterations following sympathetic nerve fiber electrostimulation. Eur Urol 1994; 26: 67–70.PubMedGoogle Scholar
  49. 49.
    Foster RS, Bennett R, Bihrle R, et al. A preliminary report: postoperative fertility assessment in nerve-sparing RPLND patients. Eur Urol 1993; 23: 165–167.PubMedGoogle Scholar
  50. 50.
    Ogura K, Nakamura K, Matsuda T, et al. [Successful artificial insemination in a patient with retrograde ejaculation following retroperitoneal lymph node dissection for testicular cancer: a case report]. Hinyokika Kiyo 1993; 39: 373–376.PubMedGoogle Scholar
  51. 51.
    Umekawa T, Kiwamoto H, Iguchi M, et al. [AIH in male infertility due to retrograde ejaculation after retroperitoneal lymph node dissection]. Nippon Hinyokika Gakkai Zasshi 1991; 82: 492–495.PubMedGoogle Scholar
  52. 52.
    Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982; 127: 685–688.PubMedGoogle Scholar
  53. 53.
    Brenner J, Vugrin D, Whitmore WFJ. Effect of treatment on fertility and sexual function in males with metastatic nonseminomatous germ cell tumors of testis. Am J Clin Oncol 1985; 8: 178–182.PubMedCrossRefGoogle Scholar
  54. 54.
    Fossa SD, Ous S, Abyholm T, et al. Post-treatment fertility in patients with testicular cancer. I. Influence of retroperitoneal lymph node dissection on ejaculatory potency. Br J Urol 1985; 57: 204–209.PubMedCrossRefGoogle Scholar
  55. 55.
    Ohl DA, Denil J, Bennett CJ, et al. Elec-troejaculation following retroperitoneal lymph-adenectomy. J Urol 1991; 145: 980–983.PubMedGoogle Scholar
  56. 56.
    Fried P, Steinfeld R, Casileth B, et al. Incidence of developmental handicaps among the offspring of men treated for testicular seminoma. Int J Androl 1987; 10: 385–387.PubMedCrossRefGoogle Scholar
  57. 57.
    Hansen PV, Glavind K, Panduro J, et al. Paternity in patients with testicular germ cell cancer: pretreatment and post-treatment findings. Eur J Cancer 1991; 27: 1385–1389.PubMedCrossRefGoogle Scholar
  58. 58.
    Bracken RB, Smith KD. Is semen cryopres-ervation helpful in testicular cancer? Urology 1980; 15: 581–583.PubMedCrossRefGoogle Scholar
  59. 59.
    Sanger WG, Armitage JO, Schmidt MA. Feasibility of semen cryopreservation in patients with malignant disease. JAMA 1980; 244: 789–790.PubMedCrossRefGoogle Scholar
  60. 60.
    Kolodziej FB, Katzorke T, Propping D. [Cryopreservation of human spermatozoa—evaluation of 93 semen depots]. Andrologia 1990; 22: 164–170.PubMedCrossRefGoogle Scholar
  61. 61.
    Ragni G, Caccamo AM, Dalla Serra A, et al. Computerized slow-staged freezing of semen from men with testicular tumors or Hodgkin’s disease preserves sperm better than standard vapor freezing. Fertil Steril 1990; 53: 1072–1075.PubMedGoogle Scholar
  62. 62.
    Sharma RK, Tolentino MV, Thomas AJ, et al. Optimal dose and duration of exposure to artificial stimulants in cryopreserved human spermatozoa. J Urol 1996; 155: 568–573.PubMedCrossRefGoogle Scholar
  63. 63.
    Agarwal A, Sidhu RK, Shekarriz M, et al. Optimum abstinence time for cryopreservation of semen in cancer patients. J Urol 1995; 154: 86–88.PubMedCrossRefGoogle Scholar
  64. 64.
    Sanger WG, Olson JH, Sherman JK. Semen cryobanking for men with cancer-criteria change. Fertil Steril 1992; 58: 1024–1027.PubMedGoogle Scholar
  65. 65.
    Scammell GE, White N, Stedronska J, et al. Cryopreservation of semen in men with testicular tumor or Hodgkin’s disease: results of artificial insemination of their partners. Lancet 1985; 2: 31–32.PubMedCrossRefGoogle Scholar
  66. 66.
    Khalifa E, Oehninger S, Acosta AA, et al. Successful fertilization and pregnancy outcome in in-vitro fertilization using cryopreserved/thawed spermatozoa from patients with malignant diseases. Hum Reprod 1992; 7: 105–108.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Dana A. Ohl
  • Jens Sonksen

There are no affiliations available

Personalised recommendations